INVESTORS & MEDIA

Press Releases

Year

Precision BioSciences Reports Second Quarter 2019 Financial Results and Highlights Ongoing Operational Progress

August 14, 2019

DURHAM, N.C., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced financial results for the second quarter ended June...

Precision BioSciences Opens First In-House cGMP Manufacturing Facility Dedicated to Genome-Edited Allogeneic CAR T Cell Therapy in the United States

July 18, 2019

Research Triangle Park Facility to Manufacture Precision’s Pipeline of Off-the-Shelf CAR T Product Candidates to Support Clinical Trials DURHAM, N.C., July 18, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the...

Elo Life Systems’ Mario G. Pennisi Awarded BIO Leadership and Legacy Award in Industrial Biotechnology and Agriculture at BIO World Congress

July 10, 2019

DURHAM, N.C. and BRISBANE, Australia, July 10, 2019 (GLOBE NEWSWIRE) -- Elo Life Systems Inc. (“Elo”), a wholly owned subsidiary of Precision BioSciences, Inc. (Nasdaq: DTIL) announced today that Mario G. Pennisi, Resident Director of Elo’s Australian subsidiary located in Brisbane, Australia,...

Precision BioSciences Appoints Dario Scimeca as General Counsel

June 12, 2019

DURHAM, N.C., June 12, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary ARCUS ® genome editing platform, announced today that Dario Scimeca has joined Precision BioSciences as General...

Precision BioSciences to Present at Upcoming Investor Conferences

May 29, 2019

DURHAM, N.C., May 29, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary ARCUS ® genome editing platform, today announced that members of its management team will participate in three...

Precision BioSciences Appoints Christopher R. Heery, M.D., as Chief Medical Officer

May 14, 2019

DURHAM, N.C., May 14, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary ARCUS® genome editing platform, announced today that Christopher R. Heery, M.D....

Precision BioSciences Announces Presentations at the 14th Annual Terrapinn World Advanced Therapies & Regenerative Medicine Congress & Expo 2019

May 9, 2019

DURHAM, N.C., May 09, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS ® genome editing platform, announced today that its Chief Scientific Officer, Derek Jantz, Ph.D., and Senior...

Precision BioSciences Reports First Quarter 2019 Financial Results

April 29, 2019

DURHAM, N.C., April 29, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, a genome editing company dedicated to improving life (Nasdaq: DTIL) (“Precision”) through the application of its proprietary ARCUS genome editing platform, announced today financial and corporate results for the first quarter...

Precision BioSciences Announces Presentations at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy

April 24, 2019

DURHAM, N.C., April 24, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS ® genome editing platform, announced today its participation in several preclinical presentations and a...

Precision BioSciences Announces Dosing of First Patient in Off-The-Shelf CAR T Cell Therapy Phase 1/2a Clinical Trial

April 17, 2019

First NHL patient treated with allogeneic CAR T in U.S.-based trial DURHAM, N.C. , April 17, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS ® genome editing platform, announced...

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 16

INVESTORS & MEDIA

Overview
Corporate Governance
Press Releases
Events & Presentations
Stock Information
SEC Filings
Investor FAQs
Corporate Deck

Investor Tools

Print Page
Email Page
Email Alerts
Document Request
Contact IR
RSS Feeds

INVESTORS & MEDIA

Press Releases

Press Releases

INVESTORS & MEDIA

Investor Tools

Contact Info

919.314.5512

About Us

Quick Links

Legal